Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Viatris Inc.NASDAQ: VTRS

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA grows, but more slowly than its trailing trend

Q2 FY2026 EBITDA of $729M rose 26.2% year over year, behind the +650.7% change in trailing-twelve-month EBITDA. Sequentially, it rose 13.2% from the prior quarter.

Context

  • EBITDA amounted to 2.8% of revenue in FY2025, down 15.1 pp from a year earlier.
  • EBITDA increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of $6.67B (+1786.3%) for the fiscal year ending Dec 2026, a step up from the -115.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$729M+13.2% QoQ
Last fiscal yearDec 2025
-$395.4M-115.0% YoY
LTMJun 2026
$2.72B+650.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.2%+116.3%+90.2 pp
1 year-115.0%+1786.3%+1901.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(395.4M) USD
Year-over-year change
-115.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How VTRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +650.7% is the highest of 9, against a peer median of -21.7%.
  • EBITDA amounts to 18.4% of revenue for VTRS, versus a peer median of 20.9%.
VTRS Competitors
EBITDA for VTRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹53.96B INR-45.2%+3.8%16.3%
HLNHaleon plcLTM Jun 2025£4.04B GBP—+9.7%24.4%
VTRSViatris Inc.LTM Jun 2026$2.72B USD+650.7%—18.4%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$2.59B USD-12.9%—15.0%
BHCBausch Health Companies Inc.LTM Jun 2026$2.05B USD-37.3%+3.4%18.9%
OGNOrganon & Co.LTM Sep 2026$1.29B USD-17.3%-9.8%21.2%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$652.2M USD+11.7%+11.1%20.9%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$234.71M USD+251.0%+102.3%25.4%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$191.41M USD-26.2%+13.3%26.6%
ALKSAlkermes plcLTM Sep 2026$178.67M USD-59.0%+76.9%10.2%
Peer median (excluding VTRS) —-21.7%+10.4%20.9%

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.89B16.26B15.43B14.74B14.3B
Cost of Revenue12.31B9.77B8.99B9.12B9.29B
Gross Profit5.58B6.5B6.44B5.62B5.01B
Gross Margin31.2%40.0%41.7%38.2%35.1%
Research & Development681M662.2M805.2M808.7M965.9M
Selling, General & Admin4.53B4.18B4.65B4.43B3.79B
Operating Expenses5.61B4.88B5.67B5.61B7.68B
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
EBITDA4.48B6.43B3.52B2.64B(395.4M)
EBITDA Margin25.0%39.6%22.8%17.9%-2.8%
Operating Income(34M)1.61B766.2M10.1M(2.66B)
Operating Margin-0.2%9.9%5.0%0.1%-18.6%
Interest Income00000
Interest Expense636.2M592.4M573.1M550M471.3M
Other Income / Expenses(630.4M)1.2B(563.3M)(633.3M)(1B)
Income Before Tax(664.4M)2.81B202.9M(623.2M)(3.67B)
Pre-Tax Margin-3.7%17.3%1.3%-4.2%-25.6%
Income Tax Expense604.7M734.6M148.2M11M(150.1M)
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Net Margin-7.1%12.8%0.4%-4.3%-24.6%
EPS (Basic)(1.05)1.710.05(0.53)(3.00)
EPS (Diluted)(1.05)1.710.05(0.53)(3.00)
Weighted Avg Shares1.21B1.21B1.2B1.19B1.17B
Weighted Avg Shares (Diluted)1.21B1.22B1.21B1.19B1.17B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.